Navigation Links
Warning Issued by FDA on consumption of the drug Tysabri used to treat Multiple Sclerosis

Recently the Food and Drug Administration (FDA) issued a public health advisory to inform patients and health care // providers about the suspended marketing of Tysabri (nataluzimab) the drug meant to treat relapsing forms of multiple sclerosis (MS) which was approved by the FDA in 2004.

FDA supports the decision to voluntarily suspend marketing of the drug as well as the use of the product in clinical trials. However, it is believed that the drug has a promising role to play in treating multiple sclerosis.

Patients being treated with Tysabri have been asked to contact their physician to discuss appropriate alternative treatments while the reports are being evaluated.

A single fatality and one possible case of progressive Multifocal leukoencephalopathy (PML) have been reported in patients receiving Tysabri for MS. However, this adverse effect was not reported when trials were conducted before the marketing phase. Post-marketing studies have facilitated the rapid reporting and response to this new information.

Because Tysabri was just recently approved, these patients have only received at most a few doses of Tysabri and the FDA says it will maintain a close contact with the company during the process to study the relationship between Tysabri and the two serious adverse events.


'"/>




Page: 1

Related medicine news :

1. Early Warning System For Breast Cancer
2. Warning on radiowave exposure
3. A Seizure Late In Life Could be A Stroke Warning
4. Blood Pressure An Early Warning Sign Of Alzheimer’s Disease
5. Early Warning Signs Of Heart Disease
6. Warning issued by FDA over "Liqiang 4 Capsules"
7. Warning Signs On Powered Baby Milk
8. People Still Neglect To Use Sunscreen In Spite Of Cancer Warnings
9. Global Outbreak Of Bird Flu Warning By Chinese Scientist
10. Experts Building Bird Flu Warning System
11. A Warning For Western Diet Followers!
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:5/26/2016)... ... ... Despite last week’s media reports hinting at a June rate hike after the Federal ... an interest rate increase, according to Rajeev Dhawan of the Economic Forecasting Center at ... Committee (FOMC) dot charts are of interest to the press for their noise potential,” ...
(Date:5/26/2016)... Missouri (PRWEB) , ... May 26, 2016 , ... ... quality and clinical outcomes, hosted members and suppliers for its inaugural Member Conference ... focus on their mission of elevating the operational health of America’s healthcare providers. ...
(Date:5/26/2016)... ... , ... The Woodlands at John Knox Village , Florida’s first Life ... living and healing, celebrated its grand opening, today. The Woodlands at John Knox Village ... Empowered Staff. , “This is an incredibly fulfilling time for John Knox Village as ...
(Date:5/26/2016)... ... 2016 , ... Catalent Pharma Solutions, the leading global provider ... global clinical supply services, today announced two key appointments and the opening of ... strategic growth plans in the Asia Pacific region. , Howard Kim has joined ...
(Date:5/26/2016)... ... May 26, 2016 , ... Memorial Day Weekend marks the unofficial ... is sharing tips to make sure your family and vehicle are ready to ... Council, there may be 439 deaths and an additional 50,500 serious injuries from motor ...
Breaking Medicine News(10 mins):
(Date:5/26/2016)... -- A key trend that will boost ... new treatments. Cardax, a development stage life sciences company, ... is expected to fulfil large unmet medical needs in ... to develop new treatments for osteoarthritis. One such study ... osteoarthritis are being investigated, and early trials of stem-cell ...
(Date:5/26/2016)... May 26, 2016 Since its ... into an essential life science tool for conducting genetic ... BCC Research reveals in its new report that the ... phase, one powered by a range of new applications ...      (Logo: http://photos.prnewswire.com/prnh/20140723/694805 ) , ...
(Date:5/25/2016)... , Deutschland und GERMANTOWN, Maryland ... Zusammenarbeit mit Therawis bedient dringenden ... Brustkrebs   QIAGEN N.V. (NASDAQ: ... heute bekannt, eine Lizenz- und Entwicklungsvereinbarung mit Therawis ... für die Onkologie eingegangen zu sein. Ein erstes ...
Breaking Medicine Technology: